Cost of Depression in Japanese Patients with Rheumatoid Arthritis: Evidence from Administrative Data

Guelfucci, F; Kaneko, Yuko; Mahlich, Jörg; Sruamsiri, Rosarin

doi:10.1007/s40744-018-0096-4

Cited by 16 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is growing evidence that depression is a common comorbidity among RA patients [41][42][43][44][45][46] and that it is associated with a significant burden of illness [47,48]. While prevalence of depression varies across studies, it has been estimated to be as high as 42% among RA patients [49].…”

Section: Discussionmentioning

confidence: 99%

Shared Decision-Making and Patient Satisfaction in Japanese Rheumatoid Arthritis Patients: A New “Preference Fit” Framework for Treatment Assessment

2019

Self Cite

View full text Add to dashboard Cite

Introduction We have developed a new framework to assess shared decision-making (SDM) as a tool to improve patient satisfaction. This framework is based on a “preference fit” index that relates SDM to patient treatment preferences and patient satisfaction in a sample of rheumatoid arthritis (RA) patients in Japan. Methods We surveyed 500 RA patients in Japan and explored the interactions between the treatment preference fit index, SDM, and overall patient satisfaction. Results Our new preference fit index reveals significant impact on patient satisfaction: the better the fit between SDM and patient preferences, the higher the patient satisfaction with the current treatment. Patients treated with biologic agents were more satisfied. Patients suffering from depression or migraines scored significantly lower both on our preference fit measure and for overall patient satisfaction. Conclusion The association between depression and a low treatment preference fit suggests that depression may pose challenges to SDM and that doctors in Japan are less attuned to the SDM preferences of depressed patients. Funding Janssen Pharmaceutical KK.

show abstract

Section: Discussionmentioning

confidence: 99%

Shared Decision-Making and Patient Satisfaction in Japanese Rheumatoid Arthritis Patients: A New “Preference Fit” Framework for Treatment Assessment

2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…This is a national administrative database of approximately 4,400,000 patients that represent approximately 3% of the total Japanese population. [ 20 ] Previously, the MDV database has been used to examine a wide range of medical conditions in Japan such as rheumatoid arthritis, [ 21 – 23 ] schizophrenia, [ 24 ] infectious diseases, [ 25 ] multiple sclerosis, [ 26 ] hypertension, [ 27 ] or prostate cancer. [ 28 , 29 ] We considered the inpatient claims from patients with hospital admission between April 1, 2014 and March 31, 2015 and at least 1 confirmed RSV-related diagnosis (International Classification of Diseases 10th Revision codes: J12.1, J20.5, J21.0, and B34.8) as well as a minimum hospital stay of 2 days (confirmed by at least 1-night stay in the hospital).…”

Section: Methodsmentioning

confidence: 99%

Hospitalization costs and length of stay of Japanese children with respiratory syncytial virus

Sruamsiri

Kubo²,

Mahlich

2018

Medicine

Self Cite

View full text Add to dashboard Cite

Background:This study sought to identify factors that impact the total health care costs associated with hospitalization of young Japanese children with respiratory syncytial virus (RSV).Methods:Children admitted between April 2014 and March 2015 with at least a confirmed diagnosis of RSV and 2 days of hospital stay were considered for inclusion. Data analyses of hospital claims were performed using a structural equation modeling approach.Results:A total of 6811 Japanese inpatients (<5 years old) diagnosed with RSV were included. The average length of stay was 7.5 days with a mean total health care cost of US Dollars (USD) $3344 per hospitalization. Intensive care unit hospitalizations were associated with greater costs (USD +$4951) compared to routine hospitalizations. The highest procedure-related cost drivers were blood transfusions (USD +$6402) and tube feedings (USD +$3512).Conclusion:The economic burden of RSV-related infection hospitalizations in Japan is considerable. Efforts should be toward immunization and therapeutic treatment strategies that reduce severity, prevent, or reduce the duration of hospitalization.

show abstract

“…Costs that occur outside this hospital network are not captured. The database had been used in health economic or epidemiological analyses of many different indications such as schizophrenia [ 15 ], influenza [ 16 ], infectious diseases [ 17 ], RA [ 18 , 19 ], cardiovascular disease [ 20 ], diabetes [ 21 ], and prostate cancer [ 22 , 23 ]. The time span of our analysis was from March 2009 to September 2015.…”

Section: Methodsmentioning

confidence: 99%

Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs

Sruamsiri

Kameda

Mahlich

2018

Drugs - Real World Outcomes

Self Cite

View full text Add to dashboard Cite

ObjectiveThe study assessed persistence rates of biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis in Japan and compared resource utilization and treatment costs between persistence and non-persistence groups.MethodsData were extracted from a Japanese claims database between 2009 and 2015. bDMARD-naïve patients were identified and included in the final analysis. Survival analysis was used to estimate 1-year persistence rates for current bDMARDs. Propensity score matching was applied to control for potential treatment selection bias. Resource utilization and healthcare costs were calculated 1 year before and after initiation of bDMARDs and compared between persistence and non-persistence groups.ResultsA total of 6153 bDMARD-naïve patients were identified and the overall 1-year persistence rate was 85% (95% CI 84–86). Overall, 1-year outpatient visits increased from 10 at baseline to 16 after bDMARD treatment, while the number of hospital admissions declined from 3.3 to 1.6. The non-persistence group had a larger increase in outpatient visits after bDMARD initiation compared with the persistence group (8–16 vs. 10–16, respectively) and a smaller decrease in hospital admissions (3.1–1.9 vs. 3.5–1.4, respectively). Persistence was associated with a reduction in total healthcare costs of US$760.ConclusionsJapanese bDMARD-naïve patients with RA have a high persistence rate with those treatments. The reduction in medication costs in non-persistent patients is offset by higher hospitalization costs, making non-persistence more expensive.Electronic supplementary materialThe online version of this article (10.1007/s40801-018-0139-8) contains supplementary material, which is available to authorized users.

show abstract

Cost of Depression in Japanese Patients with Rheumatoid Arthritis: Evidence from Administrative Data

Cited by 16 publications

References 30 publications

Shared Decision-Making and Patient Satisfaction in Japanese Rheumatoid Arthritis Patients: A New “Preference Fit” Framework for Treatment Assessment

Shared Decision-Making and Patient Satisfaction in Japanese Rheumatoid Arthritis Patients: A New “Preference Fit” Framework for Treatment Assessment

Hospitalization costs and length of stay of Japanese children with respiratory syncytial virus

Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs

Contact Info

Product

Resources

About